What are the combination treatment options with adagrasib?

Adagrasib is a small molecule drug that specifically targets the KRAS G12C mutation. Its monotherapy has shown certain anti-tumor activity. However, given the strong adaptability of tumor cells and the cross-activation characteristics of signaling pathways, combination therapy is becoming an important direction for the future clinical strategy of adagrasib. Currently, in studies at multiple cancer centers around the world, the combination of adagrasib with other targeted drugs, chemotherapy drugs, or immune checkpoint inhibitors is being actively explored in order to enhance efficacy, delay drug resistance, and improve long-term survival rates.

In the field of non-small cell lung cancer (NSCLC), adagrasib is used in combination with PD-1 inhibitors (such as pembrolizumab) to show synergistically enhanced therapeutic potential for patients with KRAS G12C mutations and positive PD-L1 expression. This combined model aims to use targeted drugs to reduce tumor burden while activating the immune system to eliminate remaining cancer cells. Another research direction is to combine adagrasib with MEK inhibitors to further inhibit the RAS-MAPK downstream signaling pathway. This pathway is considered to potentially improve the sustained response rate in some drug-resistant models.

In addition, in the treatment of colorectal cancer (CRC), the combination of adagrasib and EGFR inhibitors (such as cetuximab) has also achieved initial positive responses. This combination is mainly targeted at patients with KRAS G12C mutations and EGFR signaling pathway dependence, and enhances tumor control through dual blockade. In the future, it may also be expanded to combine adagrasib with SH2, PI3K or mTOR inhibitors to combat more complex signal escape mechanisms.

Overall, adagrasib's combination treatment strategy aims to break through the bottleneck of resistance to targeted therapy, prolong clinical benefit time, and is expected to expand application scenarios in more tumor types. As relevant research data continues to be updated, these combination regimens may gradually become standard treatment options in a variety of advanced solid tumors.

Reference materials：https://www.krazati.com/